DOP2010000185A - Antagonistas del receptor mineralcorticoide - Google Patents

Antagonistas del receptor mineralcorticoide

Info

Publication number
DOP2010000185A
DOP2010000185A DO2010000185A DO2010000185A DOP2010000185A DO P2010000185 A DOP2010000185 A DO P2010000185A DO 2010000185 A DO2010000185 A DO 2010000185A DO 2010000185 A DO2010000185 A DO 2010000185A DO P2010000185 A DOP2010000185 A DO P2010000185A
Authority
DO
Dominican Republic
Prior art keywords
formula
compound
mineralcorticoid
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DO2010000185A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2010000185A publication Critical patent/DOP2010000185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de Fórmula (I): Fórmula (I) o una sal del mismo farmacéuticamente aceptable; composiciones farmacéuticas que comprende un compuesto de Fórmula (I) en combinación con un portador, diluyente o excipiente adecuado; y métodos para tratar trastornos fisiológicos, particularmente insuficiencia cardiaca congestiva, nefropatía diabética, o enfermedad renal crónica, que comprende administrar un compuesto de Fórmula (I), o una sal del mismo farmacéuticamente aceptable.
DO2010000185A 2007-12-19 2010-06-17 Antagonistas del receptor mineralcorticoide DOP2010000185A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
DOP2010000185A true DOP2010000185A (es) 2010-09-15

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000185A DOP2010000185A (es) 2007-12-19 2010-06-17 Antagonistas del receptor mineralcorticoide

Country Status (34)

Country Link
US (1) US7994164B2 (es)
EP (2) EP2235007B1 (es)
JP (1) JP5562866B2 (es)
KR (1) KR101254382B1 (es)
CN (1) CN101903377B (es)
AR (1) AR069554A1 (es)
AU (1) AU2008343524B2 (es)
BR (1) BRPI0820805A2 (es)
CA (1) CA2710409C (es)
CL (1) CL2008003600A1 (es)
CO (1) CO6300953A2 (es)
DK (1) DK2235007T3 (es)
DO (1) DOP2010000185A (es)
EA (1) EA017668B1 (es)
EC (2) ECSP10010266A (es)
ES (2) ES2459318T3 (es)
GT (1) GT201000179A (es)
HK (1) HK1144284A1 (es)
HR (1) HRP20120916T1 (es)
IL (1) IL206353A (es)
MA (1) MA31910B1 (es)
MX (1) MX2010006911A (es)
MY (1) MY150474A (es)
NZ (1) NZ586300A (es)
PE (1) PE20091057A1 (es)
PL (1) PL2235007T3 (es)
PT (1) PT2235007E (es)
RS (1) RS52594B (es)
SI (1) SI2235007T1 (es)
TN (1) TN2010000292A1 (es)
TW (1) TWI431010B (es)
UA (1) UA100131C2 (es)
WO (1) WO2009085584A1 (es)
ZA (1) ZA201004257B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2406252B1 (en) * 2009-03-12 2015-05-20 Eli Lilly and Company Mineralocorticoid receptor antagonist and methods of use
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AU2014261070A1 (en) 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
HUE042370T2 (hu) 2014-06-30 2019-06-28 Astrazeneca Ab Benzoxazinon-amidok mint mineralokortikoid-receptor modulátorok
EA201790868A1 (ru) * 2014-11-21 2017-10-31 Эли Лилли Энд Компани 1,2-бензотиазольные соединения для лечения почечного расстройства
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CU24569B1 (es) * 2016-09-24 2022-01-13 Kbp Biosciences Co Ltd Composición farmacéutica como antagonista del receptor de mineralocorticoides
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-02-06 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
JP2002541144A (ja) 1999-01-26 2002-12-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 医薬的に活性のある化合物及びその使用方法
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CN101365696A (zh) 2004-07-28 2009-02-11 Irm责任有限公司 作为类固醇激素核受体调节剂的化合物和组合物
ES2547724T3 (es) 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
PT2089367E (pt) 2006-10-31 2012-02-01 Pfizer Prod Inc Compostos de pirazolina como antagonistas dos receptores mineralcorticóides
WO2008119918A1 (en) 2007-03-29 2008-10-09 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
JP2011510073A (ja) 2008-01-25 2011-03-31 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１アゴニストとして作用するジヒドロ−１Ｈ−ピロロ［１，２−ａ］インドール−１−イルカルボン酸誘導体
EP2406252B1 (en) 2009-03-12 2015-05-20 Eli Lilly and Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
WO2009085584A1 (en) 2009-07-09
DK2235007T3 (da) 2012-12-17
TWI431010B (zh) 2014-03-21
JP2011507868A (ja) 2011-03-10
CN101903377A (zh) 2010-12-01
CA2710409A1 (en) 2009-07-09
PE20091057A1 (es) 2009-07-20
KR101254382B1 (ko) 2013-04-15
SI2235007T1 (sl) 2013-01-31
CL2008003600A1 (es) 2010-02-19
EA201070762A1 (ru) 2010-12-30
CO6300953A2 (es) 2011-07-21
UA100131C2 (uk) 2012-11-26
RS52594B (en) 2013-04-30
MY150474A (en) 2014-01-30
ECSP10010266A (es) 2010-07-30
ES2459318T3 (es) 2014-05-09
PT2235007E (pt) 2013-01-22
IL206353A0 (en) 2010-12-30
AR069554A1 (es) 2010-02-03
KR20100082866A (ko) 2010-07-20
ECSP12012048A (es) 2012-08-31
ZA201004257B (en) 2011-11-30
TW200930721A (en) 2009-07-16
EP2537845A1 (en) 2012-12-26
ES2396605T3 (es) 2013-02-22
EA017668B1 (ru) 2013-02-28
EP2235007B1 (en) 2012-10-31
TN2010000292A1 (en) 2011-11-11
GT201000179A (es) 2012-04-16
EP2537845B1 (en) 2014-03-19
MX2010006911A (es) 2010-10-05
EP2235007A1 (en) 2010-10-06
US7994164B2 (en) 2011-08-09
MA31910B1 (fr) 2010-12-01
JP5562866B2 (ja) 2014-07-30
US20090163472A1 (en) 2009-06-25
HK1144284A1 (en) 2011-02-11
IL206353A (en) 2014-06-30
HRP20120916T1 (hr) 2012-12-31
PL2235007T3 (pl) 2013-03-29
AU2008343524B2 (en) 2012-03-08
BRPI0820805A2 (pt) 2015-06-16
CA2710409C (en) 2012-11-06
CN101903377B (zh) 2014-07-09
AU2008343524A1 (en) 2009-07-09
NZ586300A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
DOP2010000185A (es) Antagonistas del receptor mineralcorticoide
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
MX2010004503A (es) Compuesto de oxadiazolidinediona.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
UA106611C2 (uk) Інгібітори зовнішнього медулярного калієвого каналу нирок
ECSP099509A (es) Procedimiento para la preparación de un derivado de bencimidazol
MX346186B (es) Inhibidores de proteina cinasas.
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
MX2014010364A (es) Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo.
CR20210085A (es) Compuestos de 2,6-diaminopiridina
WO2007146900A3 (en) Antihypertensive therapy method
ECSP21091203A (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
MX2016000188A (es) Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan.